Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 3 N=701 Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 3 N=554 Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 58.06; NA Months
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 2 N=19 A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Dose Limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
Phase 3 N=602 A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 324; 241 days — p=0.00583
Phase 2 N=101 Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
Phase 2 N=30 A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Proportion of Subjects Achieving Disease Control (Non-progressive Disease) at 8 Weeks After Initiation of Treatment — 0.7273; 0.6429 Proportion of evaluable participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 4 N=1,044 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy
Hepatic Carcinoma
Primary: Incidence of Recurrence and Metastasis After Hepatectomy — 428; 155; 258; 161 Participants — p=0.0001
Phase 3 N=720 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Overall Survival — 289; 259 Days
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 2 N=16 A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
Hepatocellular Carinoma
Primary: Number of Participants With Radiographic Response — 4 Participants
Phase 2 N=76 Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
Liver Cancer · Hepatocellular Carcinoma
Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants
Phase 3 N=458 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)
Carcinoma, Hepatocellular
Primary: Time to Progression (TTP) — 164; 112 days
Phase 2 N=21 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability. — 16; 5 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
N/A N=109 STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Localized Hepatocellular Carcinoma
Primary: Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging) — 75; 73 participants
Phase 2 N=27 Sorafenib and TRC105 in Hepatocellular Cancer
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Phase 2 N=29 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Median Time to Progression (TTP) — 3.7 months
Phase 1 N=18 Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation
Liver Cirrhosis · Hepatocellular Carcinoma · Evidence of Liver Transplantation
Primary: Side Effect of Cadaveric Donor Liver NK Cell Infusion — 0; 0 participants
Phase 1 N=6 MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072